RT Journal Article
SR Electronic
T1 A viral perspective on worldwide non-pharmaceutical interventions against COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.24.20180927
DO 10.1101/2020.08.24.20180927
A1 Rasigade, Jean-Philippe
A1 Barray, Anaïs
A1 Shapiro, Julie Teresa
A1 Coquisart, Charlène
A1 Vigouroux, Yoann
A1 Bal, Antonin
A1 Destras, Grégory
A1 Vanhems, Philippe
A1 Lina, Bruno
A1 Josset, Laurence
A1 Wirth, Thierry
YR 2020
UL http://medrxiv.org/content/early/2020/10/31/2020.08.24.20180927.abstract
AB Quantifying the effectiveness of large-scale non-pharmaceutical interventions (NPIs) against COVID-19 is critical to adapting responses against future waves of the pandemic. Most studies of NPIs thus far have relied on epidemiological data. Here, we report the impact of NPIs on the evolution of SARS-CoV-2, taking the perspective of the virus. We examined how variations through time and space of SARS-CoV-2 genomic divergence rates, which reflect variations of the epidemic reproduction number Rt, can be explained by NPIs and combinations thereof. Based on the analysis of 5,198 SARS-CoV-2 genomes from 57 countries along with a detailed chronology of 9 non-pharmaceutical interventions during the early epidemic phase up to May 2020, we find that home containment (35% Rt reduction) and education lockdown (26%) had the strongest predicted effectiveness. To estimate the cumulative effect of NPIs, we modelled the probability of reducing Rt below 1, which is required to stop the epidemic, for various intervention combinations and initial Rt values. In these models, no intervention implemented alone was sufficient to stop the epidemic for Rt’s above 2 and all interventions combined were required for Rt’s above 3. Our approach can help inform decisions on the minimal set of NPIs required to control the epidemic depending on the current Rt value.Competing Interest StatementBL is currently active in groups advising the French government for which BL is not receiving payment.Funding StatementJPR received support from the FINOVI Foundation (grant R18037CC).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicable.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesBoth data and analysis code are available online at https://github.com/rasigadelab/covid-npi. https://github.com/rasigadelab/covid-npi